Jonathan Kell

3.7k citations
57 papers · 2.8k · 1 hit paper · h-index 21

Impact in

  • Hematology top 0.5%
    • Acute Myeloid Leukemia Research
    • Hematopoietic Stem Cell Transplantation
    • Multiple Myeloma Research and Treatments
  • Genetics top 2%
    • Myeloproliferative Neoplasms: Diagnosis and Treatment

Papers in

    • Acute Myeloid Leukemia Research 37
    • Multiple Myeloma Research and Treatments 9
    • Chronic Myeloid Leukemia Treatments 5
    • Chronic Lymphocytic Leukemia Research 6
    • Myeloproliferative Neoplasms: Diagnosis and Treatment 5

Jonathan Kell

56 papers receiving 2.7k citations

Jonathan Kell's Hit Papers

Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial 2010 · 530 citations
5300+5+10Years since publication100200300400500

Peers

Jonathan Kell
Comparison fields: 5 of 84
  • Hematology 2.0k
  • Genetics 375
  • Public Health, Environmental and Occupational Health 596
  • Oncology 514
  • Biochemistry 117
Replace Lars Möllgård with:
Lars Möllgård Sweden
Åsa Rangert Derolf Sweden
Georgine E. de Greef Netherlands
Eytan M. Stein United States
Susan A. O'Brien United States
Mark Brandt United States
Michael J. Barnett Canada
G. L. Phillips Canada
Z. A. Arlin United States
Musa E. Yilmaz United States
Jonathan Kell relative to Lars Möllgård Sweden Lars Möllgård's profile →
Citations per field
00.5×1.6×
Lars Möllgård · 1×
Citations per year

Countries citing papers authored by Jonathan Kell

Since Specialization
Citations

This map shows the geographic impact of Jonathan Kell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathan Kell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathan Kell more than expected).

Fields of papers citing papers by Jonathan Kell

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jonathan Kell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathan Kell. The network helps show where Jonathan Kell may publish in the future.

Co-authors

The 25 scholars most cited alongside Jonathan Kell, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Jonathan Kell Line = papers co-authored together Jonathan Kell links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 57 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial
Hit paper breakdown →
2010530
2 2015389
3 2012326
4 2015218
5 2006150
6 2010132
7 2006112
8 200878
9 201369
10 200963
11 201662
12 201254
13 199750
14 201247
15 200942
16 201136
17 201432
18 200626
19 200623
20 202022

About Jonathan Kell

Jonathan Kell is a scholar working on Hematology, Genetics, Public Health, Environmental and Occupational Health, Oncology and Infectious Diseases, having authored 57 papers that have together received 2.8k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (37 papers), Acute Lymphoblastic Leukemia research (13 papers), Retinoids in leukemia and cellular processes (12 papers), Multiple Myeloma Research and Treatments (9 papers), Chronic Lymphocytic Leukemia Research (6 papers), HIV/AIDS drug development and treatment (5 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (5 papers) and Chronic Myeloid Leukemia Treatments (5 papers). The work is most often cited by research in Hematology (2.0k citations), Genetics (375 citations), Public Health, Environmental and Occupational Health (596 citations), Oncology (514 citations) and Biochemistry (117 citations). Jonathan Kell has collaborated with scholars based in United Kingdom, United States and Denmark. Frequent co-authors include Alan K. Burnett, Nigel H. Russell, Robert K. Hills, Keith Wheatley, Lars Kjeldsen, Donald William Milligan, Ann Hunter, Anthony H. Goldstone, John A. Liu Yin and David J. Grimwade. Their work appears in journals such as Blood, British Journal of Haematology, Journal of Clinical Oncology, Leukemia and Frontiers in Pharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact